Initial Results of a Phase 2 Study of Venetoclax Added to Ibrutinib to Eliminate Ibrutinib Resistance Mutations in CLL von Rogers, Kerry A, McLaughlin, Eric, Wei, Lai, Bhat, Seema A, Crouse, Arianna, Grever, Michael R., Jones, Dan, Kittai, Adam S, Lozanski, Gerard, Moran, Mollie, Reid, Mark, Sass, Ellen J, Suresh, Swetha, Byrd, John C., Woyach, Jennifer A.

Volltext